Chromosome 1 Abnormalities Predict Shortened Progression Free and Overall Survival in Patients with High Risk Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation, a Retrospective Analysis
Emma C. Scott1*, Yiyi Chen2 , Andy I. Chen1, Stephen D. Smith1,3, Ido Barkay4, William Dibb1, James Dibb1, Alex Stentz1, Rachel Frires1, Matthew Siegel1, Phoebe Trubowitz1, Eva Medvedova1 and Richard T. Maziarz1
- *Corresponding Author:
- Emma C. Scott, MD
The Center for Hematologic Malignancies
Oregon Health and Science University
3181 SW Sam Jackson Park Road
Portland, Oregon, USA 97239
Tel: 503 494-8311
E-mail: [email protected]
Received Date: November 22, 2014; Accepted Date: January 07, 2015; Published Date: January 15, 2015
Citation: Scott EC, Chen Y, Chen AI, Smith SD, Barkay I, et al. (2015) Chromosome 1 Abnormalities Predict Shortened Progression Free and Overall Survival in Patients with High Risk Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation, a Retrospective Analysis. J Blood Lymph 5:131. doi:10.4172/2165-7831.1000131
Copyright: © 2015 Scott EC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abnormalities of chromosome (ch)1 have been shown to be significant adverse prognostic factors in multiple myeloma (MM) but they have not yet been systematically studied in patients undergoing autologous hematopoietic cell transplantation (auto-HCT). The aim of this study was to determine whether patients with high-risk MM and ch1 abnormalities (1q gain, 1p deletion, translocations of ch1) constitute a highest risk group compared to a contemporaneous cohort of high-risk MM patients without ch1 abnormalities. 232 patients (169 induction, 63 salvage) with MM and at least one recognized high-risk feature met criteria for inclusion. The presence of a ch1 abnormality (n=15) was highly significant in patients undergoing salvage autologous HCT (n=6) for predicting shorter PFS (p<0.001; HR= 22.93; 95% CI: 4.94- 106.48), and OS (p = 0.0002; HR= 21.22; 95% CI: 1.18-14.98). Median PFS and OS for those with a ch1 abnormality and del 13q (n=7) were 4.76 and 9.43 months, with ch1 abnormality and no del 13q (n=8) were 16.79 and 35.22 months respectively, and for those Without cytogenetic abnormalities, 24.44 and 57.03 months respectively. Based upon the impact of ch1 abnormalities on auto-HCT outcomes in this study, further investigation in larger series is warranted.